Published in Gene Therapy Weekly, July 10th, 2003
Chen will present the results of preclinical studies using the company's proprietary ssDNA expression system in targeting and silencing genes. This meeting brings together world leaders in the field of gene-based drug design to explore recent advances in this exciting new approach to developing therapeutic compounds. CytoGenix has developed formulations against herpes, several inflammatory diseases, E. coli, Staphylococcus, and strep.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.